Lenalidomide and Intensive Chemotherapy for Patients with Higher-Risk MDS or AML with Del(5q)
Ades L et al. Lenalidomide (LEN) combined to intensive chemotherapy (IC) in AML and higher risk MDS with del 5q. Results of a phase I/II study of the Groupe Francophone des Myelodysplasies (GFM). Proc ASH 2010; Abstract 508.
Dr Smith is Associate Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.
|